New Agent Significantly Improves Progression-Free Survival in Patients With Advanced ER+ Breast Cancer

Article

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Combining the investigational PD 0332991 with letrozole as first-line therapy extended progression-free survival in women with advanced estrogen-receptor positive breast cancer.

Click here to view this article.

Related Videos
Kelley Branch, MD, MSc | Credit: University of Washington Medicine
Sejal Shah, MD | Credit: Brigham and Women's
Video 2 - "Differentiating Medication Non-Adherence From Underlying Comorbidities"
Video 1 - "Defining Resistant Diabetes"
Related Content
Abatacept Treatment May Slow Atherosclerosis Progression

Abatacept Treatment May Slow Atherosclerosis Progression

April 25th 2024
Article
2024 State of the Air: Record Highs in US Particle Pollution, with Dr. John Balmes

2024 State of the Air: Record Highs in US Particle Pollution, with John Balmes, MD

April 24th 2024
Podcast
Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

April 24th 2024
Article
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.

Diabetes Dialogue: 2024 ACP Type 2 Diabetes Recommendations

April 19th 2024
Podcast
Sleep of Psoriasis Patients Improves with Intensive Topical Treatment

Sleep of Psoriasis Patients Improves with Intensive Topical Treatment

April 24th 2024
Article
Juul van den Reek, MD, PhD | Credit: International Psoriasis Council

Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors

April 24th 2024
Article
© 2024 MJH Life Sciences

All rights reserved.